What is X-Linked Severe Combined Immunodeficiency?

X-linked severe combined immunodeficiency (X-SCID), caused by harmful genetic changes (variants) in the IL2RG gene, is a disorder of the immune system that causes recurrent, severe infections, fevers, and skin rashes. The IL2RG gene gives our bodies instructions for making part of a protein called the "common gamma chain," which helps our immune system function. Individuals with X-SCID are missing two critical pieces of the immune system: T lymphocytes and natural killer lymphocytes. These individuals also have B lymphocytes that do not work. Since the immune system cannot function properly, individuals with X-SCID cannot fight off infections.

X-SCID is inherited in an X-linked manner. This means the condition is typically more severe in individuals assigned male at birth (XY). Individuals assigned female at birth (XX) usually do not have symptoms of the condition.

Symptoms of typical X-SCID usually begin between three and six months of age. Most infants with untreated X-SCID will show slower than average growth, develop significant diaper and oral rashes, and have severe, persistent infections despite active treatment. Without treatment, these infections may lead to death in the first year of life. There are also atypical forms of X-SCID. Atypical forms may have immune-system dysfunction, rashes, gastrointestinal problems, recurrent respiratory infections, and short stature. They generally have a later onset than typical X-SCID, and symptoms can vary widely (even among members of the same family).

Additional considerations for carriers

Most XX individuals (who are typically assigned female at birth) are carriers of X-SCID. While most carriers do not have symptoms, there are rare cases reports of carriers affected by X-SCID.

How common is X-Linked Severe Combined Immunodeficiency?

The exact incidence of X-SCID is unknown. It is estimated to occur in 1 in 50,000 to 1 in 100,000 individuals.

How is X-Linked Severe Combined Immunodeficiency treated?

Bone marrow transplantation is the most common form of treatment for typical X-SCID. Replacement of the bone marrow in a person with typical X-SCID with the bone marrow of a healthy individual allows the body to generate new, functional blood cells and lymphocytes. Bone marrow transplantation has a significantly higher success rate if performed shortly after birth. Cord blood transplantation may also be an effective treatment for typical X-SCID. Gene therapy may also be considered for patients who are not good candidates for bone marrow or cord blood transplantation. Treatment for individuals with an atypical form of X-SCID depends on the degree of immune deficiency. An immunology specialist can help determine the appropriate management for an individual with an atypical form of X-SCID.

What is the prognosis for an individual with X-Linked Severe Combined Immunodeficiency?

Typical X-SCID is almost universally fatal unless a successful bone marrow transplantation or gene therapy is completed. Approximately 90% of infants can be successfully treated with a bone marrow transplant. For infants in which a bone marrow transplant is not entirely successful, or for those who are not candidates for a bone marrow transplant, administration of proteins to help the immune system function may be beneficial. For infants in whom bone marrow transplantation, gene therapy, or immunoglobulin infusion is unsuccessful, the average life expectancy is approximately one to two years. The prognosis of atypical forms of X-SCID varies widely, with some individuals surviving later into childhood without a bone marrow transplantation.

Benefits of X-linked severe combined immunodeficiency Carrier Screening (Genetic Testing)

Carrier screening is an important form of genetic testing for those who may be at risk of passing x-linked severe combined immunodeficiency to their baby. Carrier Screening for x-linked severe combined immunodeficiency can help in identifying that risk. The Foresight® Carrier Screen helps clinicians guide care and empowers patients to take action to make the best decision for their families. Learn more about the Foresight® Carrier Screen} by Myriad Genetics.

Other names for
X-linked severe combined immunodeficiency

  • SCIDX1
  • Swiss-type agammaglobulinemia
  • X-linked SCID
  • XSCID

References

  • Allenspach et al., 2025, GeneReviews, http://www.ncbi.nlm.nih.gov/books/NBK1410/
  • Arcas-García et al., 2020, Immunol, 200(1):61-72, PMID: 31799703
  • Briassouli et al., 2026, Front Immunol, 13:17:1703097, PMID: 41909668
  • Dvorak et al., 2023, Allergy Clin Immunol, 151(2):539-546, PMID: 36456361
  • Fischer, 2000, Clin Exp Immunol, 122(2):143-9, PMID: 11091267
  • Jacovas et al., 2026, Genet Med, 28(1):101613, PMID: 41104538
  • Puck, 1997, JAMA, 278(22):1835-41, PMID: 9396644